The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency

British Journal of Clinical Pharmacology

Volumn 47, Issue 3, 1999, Pages 273-278

  Janssen, Y J H ^b   Frolich M ^b   Roelfsema, F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Absorption; Adults; GH; GH deficiency; Somatotropin

Indexed keywords

HUMAN GROWTH HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ABSORPTION; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; TIME FACTORS;

EID: 0033037964     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00892.x     Document Type: Article

References (23)

1. 1 Jørgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; i: 1221-1225.
2. 2 Cuneo RC, Salomon F, McGauley GA, Sönksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1992; 37: 387-397.
3. 3 Bengtsson BÅ, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309-317.
4. 4 De Boer H, Blok GJ, van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995; 16: 63-86.
5. 5 Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803.
6. 6 Mårdh G, Lindeberg A, on behalf of the investigators. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined clinical safety data from clinical trials in 665 patients. Endocrinology and Metabolism 1995; 2: 11-16.
7. 7 Janssen YJH, Frölich M, Roelfsema F. A low starting dose of genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab 1997; 82: 129-135.
8. 8 Janssen YJH, Hamdy NA, Frölich M, Roelfsema F. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998; 83: 2143-2148.
9. 9 Johannsson G, Rosen T, Bengtsson BÅ. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 1997; 47: 571-581.
10. 10 Laursen T, Jørgensen JO, Christiansen JS. Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen [published erratum appears in Clin Endocrinol (Oxf) 1995 Jan;42(1): 109]. Clin Endocrinol (Oxf) 1994; 40: 373-378.
11. 11 Laursen T, Grandjean B, Jørgensen JO, Christiansen JS. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration. Eur J Endocrinol 1996; 135: 309-315.
12. 12 Vahl N, Jensen SB, Rasmussen MH, et al. Bioavailability of recombinant human growth hormone in different concentrations and formulations. Pharmacol Toxicol 1996; 79: 144-149.
13. 13 Jørgenscn JO, Flyvbjerg A, Lauritzen T, Alberti KG, OØrskov H, Christiansen JS. Dose-response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. J Clin Endocrinol Metab 1988; 67: 36-40.
14. 14 Jørgensen JO, Flyvbjerg A, Lauritzen T, Ørskov H, Christiansen JS. Subcutaneous degradation of biosynthetic human growth hormone in growth hormone deficient patients. Acta Endocrinol (Copenh) 1988; 118: 154-158.
15. 15 Laursen T, Moøller J, Joørgensen JO, Orskov H, Christiansen JS. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. Clin Endocrinol (Oxf) 1996; 45: 333-339.
16. 16 Du Dois D, Du Bois EF. Clinical calorimeter. A formula to estimate the approximate surface if height and weight be known. Arch Intern Med 1916; 17: 863-871.
17. 17 Janssen YJH. Deurenberg P, Roelfsema F. Using dilution techniques and multifrequency bioelectrical impedance to assess both total body water and extracellular water at baseline and during recombinant human growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1997; 82: 3349-3355.
18. 18 Jansson JO, Albertsson-Wikland K, Eden S, Thorngren KG, Isaksson O. Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats. Acta Physiol Scand 1982; 114: 261-265.
19. 19 Clark RG, Jansson JO, Isaksson O, Robinson IC. Intravenous growth hormone: growth responses to patterned infusions in hypophysectomizcd rats. J Endocrinol 1985; 104: 53-61.
20. 20 Isgaard J, Carlsson L, Isaksson OG, Jansson JO. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology 1988; 123: 2605-2610.
21. 21 Jørgensen JO, Moøller N, Lauritzen T, Christiansen JS. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab 1990; 70: 1616-1623.
22. 22 Shah N, Evans WS, Veldhuis JD. Mode of GH entry into the bloodstream, rather than gender or sex-steroid hormones, determines GH half-life in the human. Annual Meeting of the Endocrine Society 1997; P02:(Abstract).
23. 23 Holl RW, Schwarz U, Schauwecker P, Benz R, Veldhuis JD, Heinze E. Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. J Clin Endocrinol Metab 1993; 77: 216-220.